<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3281">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779346</url>
  </required_header>
  <id_info>
    <org_study_id>2020-10275-BO-ff</org_study_id>
    <nct_id>NCT04779346</nct_id>
  </id_info>
  <brief_title>Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting</brief_title>
  <acronym>COVIDOUT</acronym>
  <official_title>Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting: Prevalence and Serological Immunity in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVIDOUT study will prospectively investigate the serological immunity of outpatient&#xD;
      cancer patients to evaluate the prevalence of previous severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2) infections and dependency of serological immunity on systemic&#xD;
      (chemo)therapy after COVID19 disease as well as after vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective observational study all cancer patients who are regularly treated in the&#xD;
      Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE) will be&#xD;
      included in the study upon consent.&#xD;
&#xD;
      Data will be collected as follows:&#xD;
&#xD;
      (i) Serological antibody screening at study inclusion and every 3 months (ia) In case of&#xD;
      vaccination monthly screening for 3 months (ii) Routine clinical data: demographic and&#xD;
      biometric data, medical history, common laboratory parameters (iii) Patient questionnaire:&#xD;
      assessment of past COVID-19 infection, past COVID-19 specific symptoms, social environment,&#xD;
      vaccination&#xD;
&#xD;
      Recruitment is limited to a one-year period (December 2020 - December 2021)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Rate of SARS-CoV-2 antibody positive patients</measure>
    <time_frame>1 year</time_frame>
    <description>Measured in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 antibody positive patients</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Measured in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Measured in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of unknown prior COVID19 disease in SARS-CoV-2 antibody positive patients</measure>
    <time_frame>1 year</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cancer entities in SARS-CoV-2 antibody positive patients</measure>
    <time_frame>1 year</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of therapy modalities in SARS-CoV-2 antibody positive patients</measure>
    <time_frame>1 year</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Dependency of rate on cancer entity, therapy modality, age, sex and immune status [Measured in percentage]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of re-infection in SARS-CoV-2 antibody positive patients</measure>
    <time_frame>1 year</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cancer</condition>
  <condition>Covid19</condition>
  <condition>Immunity</condition>
  <arm_group>
    <arm_group_label>Outpatient cancer patients</arm_group_label>
    <description>Cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of cancer patients who are regularly treated in the Oncology&#xD;
        Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known diagnosis of cancer&#xD;
&#xD;
          -  Active disease or (in case of cure) last systemic therapy &lt;12 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Sinn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Sinn, MD</last_name>
    <phone>+49407410</phone>
    <phone_ext>0</phone_ext>
    <email>ma.sinn@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schönlein, MD</last_name>
    <phone>+49407410</phone>
    <phone_ext>0</phone_ext>
    <email>m.schoenlein@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Sinn, MD</last_name>
      <phone>+49407410</phone>
      <phone_ext>0</phone_ext>
      <email>ma.sinn@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Aggregated data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

